Skip to main content
. 2019 Oct 19;8(11):835–844. doi: 10.1002/psp4.12456

Figure 1.

Figure 1

Sample infliximab pharmacokinetic profiles in healthy subjects, ankylosing spondylitis, and rheumatoid arthritis, and a comparison of model‐predicted vs. observed infliximab concentrations. References to observed data provided in Table S1 . AAFE, absolute average fold error; IFX, infliximab; NSCLC, non‐small cell lung cancer; R 2, squared Pearson correlation coefficient; RMSE, root mean squared error.